LTR Pharma Signs Collaborative Development Agreement to Develop a Novel Intranasal Spray for Oesophageal Motility Disorders
Published: 8 May 2025
LTR Pharma Signs Collaborative Development Agreement to Develop a Novel Intranasal Spray for Oesophageal Motility Disorders
LTR Pharma has announced that it has entered into a collaborative development agreement with Strategic Drug Solutions, Inc. (SDS) to co-develop OROFLOW®, a novel intranasal spray for Oesophageal Motility Disorders (OMD).
OROFLOW® represents an important expansion of the Company’s nasal spray technology platform, designed to provide rapid symptom relief for patients struggling with swallowing difficulties, a condition that affects millions worldwide.
This collaborative development targets a substantial global market valued at $4.5 billion and projected to reach $8.1 billion by 2034. The program will commence towards Proof-of-Concept testing over the coming months.
LTR Pharma Executive Chairman, Lee Rodne, said:
“OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges for patients. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief.”
Jump to next article
5 min read